

Saxagliptin linked to improved albumin/creatinine ratios

October 25 2016



(HealthDay)—For patients with type 2 diabetes, saxagliptin is associated

with improvement in the albumin/creatinine ratio (ACR), according to a study published online Oct. 17 in *Diabetes Care*.

Ofri Mosenzon, M.D., from the Hadassah Hebrew University Hospital in Jerusalem, and colleagues studied renal outcomes of 16,492 [patients](#) with type 2 diabetes randomized to [saxagliptin](#) versus placebo and followed for a median of 2.1 years.

The researchers found that from baseline to the end of the trial, treatment with saxagliptin was associated with improvement in and/or less deterioration in ACR categories for individuals with baseline normoalbuminuria, microalbuminuria, and macroalbuminuria ($P = 0.021$; P glomerular filtration rate (eGFR) of >50 mL/min/BSA, $50 \geq$ eGFR ≥ 30 mL/min/BSA, and

Citation: Saxagliptin linked to improved albumin/creatinine ratios (2016, October 25) retrieved 4 May 2024 from <https://medicalxpress.com/news/2016-10-saxagliptin-linked-albumincreatinine-ratios.html>

| |
|--|
| <p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p> |
|--|